A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours

Pertuzumab represents the first in a new class of targeted therapeutics known as HER dimerisation inhibitors. We conducted a phase Ib study to determine the maximum-tolerated dose, the dose limiting toxicities (DLT), and pharmacokinetic (PK) interaction of docetaxel when administered in combination...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Attard, G, Kitzen, J, Blagden, S P, Fong, P C, Pronk, L C, Zhi, J, Zugmaier, G, Verweij, J, de Bono, J S, de Jonge, M
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2007
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2360237/
https://ncbi.nlm.nih.gov/pubmed/18000498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604043
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados